Johnathan Lancaster has joined Myriad Genetics as VP of Medical Affairs for Oncology, effective Feb. 9. He will provide medical and scientific leadership across the company's portfolio of molecular and companion diagnostic products and services for oncology. Lancaster will report to Lloyd Sanders, GM for the oncology business unit at Myriad Genetic Laboratories.
Lancaster has spent the past 12 years at Moffitt Cancer Center, where he's held several posts, including president of Moffitt Medical Group, deputy physician-in-chief and director of the Center for Women's Oncology, and chair of the department of women's oncology. Prior to Moffitt, he was medical director of the Gynecology Dysplasia Clinic at Duke University Medical Center.
RainDance Technologies appointed Scott Bortner its VP of intellectual property. He will be responsible for strengthening and defending the IP portfolio underlying RainDance's core digital droplet technology and applications for non-invasive, liquid biopsy research. Bortner has more than 25 years of experience in the genomics IP space and has held senior IP counsel positions at Applied Biosystems, Affymetrix, and Natera.
François Roy, Suzanne Vinet, Brian White-Guay
Génome Québec appointed François Roy, Suzanne Vinet, and Brian White-Guay to its board of directors. Roy has extensive experience as a corporate director and executive in the public and private sectors. He was with the Société générale de financement du Québec and then served as CFO for Québecor.
Vinet was deputy minister at Agriculture andAgri-FoodCanada. Previously, she was president at Canada Economic Development for Québec Regions and associate deputy minister of Health Canada.
White-Guay has been a member of AmorChem's investment committee since 2011 and joined the faculty of pharmacy at Université de Montréal as a professor in 2008. Prior to that, he was a vice president at Merck, responsible for all clinical operations and medical departments worldwide. He previously was VP of regulatory affairs for Europe for Merck.
Certara has tapped Gavin Nichols to serve in the newly created position of president of technology. Nichols will also head Cetara's software business unit. He'll be based in the company's Cary, NC office. In his new roles, Nichols will lead Certara's research and development, product management, and IT teams. He'll also be responsible for developing and positioning the company's biosimulation applications and informatics platforms.
Nichols joins Certara from Quintiles, where he served as VP of strategy/enterprise architecture/R&D innovation IT. Before that, he worked for Unisys, Collaborex, and Cap Gemini, holding positions ranging from life science practice head to EMEA general manager.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.